2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Development pipeline with significant progress<br />
Central Nervous System (CNS)<br />
Neupro ® (rotigotine)<br />
Adv. Parkinson's disease (U.S.)<br />
Neupro ® (rotigotine)<br />
Restless legs syndrome (U.S.)<br />
Xyrem ® (sodium oxybate)<br />
Fibromyalgia (EU)<br />
Vimpat ® (lacosamide)<br />
Epilepsy – monotherapy (U.S.)<br />
Vimpat ® (lacosamide)<br />
Epilepsy – monotherapy (EU)<br />
brivaracetam<br />
Epilepsy – adj. therapy<br />
Vimpat ® (lacosamide)<br />
Epilepsy – Paediatric adj. therapy<br />
Vimpat ® (lacosamide)<br />
Epilepsy – adj. therapy PGTCS<br />
<strong>UCB</strong>0942 (PPSI)<br />
Epilepsy<br />
Phase 1 Phase 2 Phase 3 Regulatory status<br />
first <strong>results</strong><br />
Results<br />
H2 <strong>2011</strong><br />
Results<br />
Q2 2013<br />
Results<br />
Q4 2014<br />
Results<br />
H1 2013<br />
Filed CRL*<br />
November Dec 2008 2008<br />
CRL*<br />
Dec 2008<br />
CRL1<br />
April Filed <strong>2010</strong><br />
�<br />
�<br />
�<br />
* Complete Response Letter<br />
40
Change language